Cambridge Healthtech Institute’s Inaugural

Targeted Oligo Delivery Using Conjugates

Innovations in Nucleic Acid Delivery Using Antibody, Peptide, LNP or Lipid Conjugates and Novel Linkers

March 17-18, 2027

Cambridge Healthtech Institute’s inaugural conference on Targeted Oligo Delivery Using Conjugates brings together chemists, biologists, and formulation experts looking to design oligo therapies using novel bioconjugates to deliver them in a tissue-specific manner. Utilizing AI/ML predictions, innovative conjugate and linker chemistries, and novel formulation and delivery techniques, these emerging organ-specific, cell-permeable, and orally bioavailable therapies are being developed to tackle challenging extra-hepatic disease indications. The talks and discussions will delve into innovations around improving efficacy, stability, bioavailability, and deliverability of these modalities, while reducing immunogenicity and safety concerns.

Coverage will include, but is not limited to:

Antibody-oligo conjugates (AOCs) and peptide-oligo conjugates: promise, pitfalls, and IND-enabling strategy
Designing and delivering oligo conjugates for extra-hepatic delivery (CNS, muscle, kidney, lung, and more)
Novel multi-modal and tunable oligo conjugates for tissue-specific, on-demand release
Innovative linker chemistries, antibody engineering, internalization mechanisms, and endogenous delivery
Target-specific lipid nanoparticle (LNP)-enabled oligo and in vivo CAR delivery
New tools (DEL screening) and methods for optimizing bioconjugation and biodistribution
AI/ML-based prediction and analysis for designing, optimizing, and selection of specific conjugates
Strategies and oligo shuttles for improving blood-brain barrier (BBB) permeability and systemic delivery
New formulations, payloads, and delivery routes for targeted cell permeability and tissue specificity
Case studies highlighting novel oligo conjugated therapies for obesity, metabolism, oncology, and more
When delivery becomes toxicity: translational safety lessons for AOCs and other oligonucleotide conjugates

The deadline for priority consideration is September 4th 2026.

Submit a Proposal »

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: